Additionally, B16 tumor cells expressed significantly less PD-L1 and significantly more MHC-II when treated with ADU-S100 + anti-PD-L1 compared to ADU-S100 alone (Supplementary Figure 4E), indicating that the combination therapy induced a more pro-inflammatory, less-immune evasive phenotype in melanoma cells as well. This evidence concerns the gene CD274 and melanoma.